Trial Profile

A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relugolix (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OPTYX
Sponsors Myovant Sciences; Sumitomo Pharma; Sumitomo Pharma America

Most Recent Events

26 Nov 2024 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 Interim results (As of October 2023, n=394) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
18 Feb 2023 Trial design presented at the 2023 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com